BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37786399)

  • 1. Colposcopy referral rates post-introduction of primary screening with human papillomavirus testing: evidence from a large British Columbia cohort study.
    Gottschlich A; Gondara L; Smith LW; Anderson JJ; Cook D; Krajden M; Lee M; Martin RE; Melnikow J; Peacock S; Proctor L; Stuart G; Franco EL; van Niekerk D; Ogilvie GS
    Lancet Reg Health Am; 2023 Oct; 26():100598. PubMed ID: 37786399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
    Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
    PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence of decreased long-term risk of cervical pre-cancer after negative primary HPV screens compared to negative cytology screens in a longitudinal cohort study.
    Gottschlich A; Hong Q; Gondara L; Alam MS; Cook DA; Martin RE; Lee M; Melinikow J; Peacock S; Proctor L; Stuart G; Franco EL; Krajden M; Smith LW; Ogilvie GS
    Cancer Epidemiol Biomarkers Prev; 2024 May; ():. PubMed ID: 38773687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Projected Impact of HPV and LBC Primary Testing on Rates of Referral for Colposcopy in a Canadian Cervical Cancer Screening Program.
    Coldman AJ; Phillips N; van Niekerk D; Smith L; Krajden M; Cook D; Quinlan DJ; Ehlen T; Miller D; Stuart GC; Peacock S; Martin RE; Franco EL; Ogilvie G
    J Obstet Gynaecol Can; 2015 May; 37(5):412-420. PubMed ID: 26168101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefits and potential harms of human papillomavirus (HPV)-based cervical cancer screening: A real-world comparison of HPV testing versus cytology.
    Thomsen LT; Kjaer SK; Munk C; Ørnskov D; Waldstrøm M
    Acta Obstet Gynecol Scand; 2021 Mar; 100(3):394-402. PubMed ID: 33566361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
    Gilham C; Sargent A; Kitchener HC; Peto J
    Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
    Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
    Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
    Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A
    J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effectiveness of Different Testing Strategies Applied for Cervical Cancer Screening in Shuangliu District, Chengdu City].
    Zeng X; Li J; Kang LN; Yan LP; He Z; Liao GD; Xi MR; Chen MY
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2022 Sep; 53(5):896-903. PubMed ID: 36224694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of standardised colposcopy to detect cervical precancer and cancer for triage of women testing positive for human papillomavirus: results from the ESTAMPA multicentric screening study.
    Valls J; Baena A; Venegas G; Celis M; González M; Sosa C; Santin JL; Ortega M; Soilán A; Turcios E; Figueroa J; Rodríguez de la Peña M; Figueredo A; Beracochea AV; Pérez N; Martínez-Better J; Lora O; Jiménez JY; Giménez D; Fleider L; Salgado Y; Martínez S; Bellido-Fuentes Y; Flores B; Tatti S; Villagra V; Cruz-Valdez A; Terán C; Sánchez GI; Rodríguez G; Picconi MA; Ferrera A; Mendoza L; Calderón A; Murillo R; Wiesner C; Broutet N; Luciani S; Pérez C; Darragh TM; Jerónimo J; Herrero R; Almonte M;
    Lancet Glob Health; 2023 Mar; 11(3):e350-e360. PubMed ID: 36796982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Different HPV-based Strategies and Cytology in Routine Cervical Cancer Screening Programme in China: A Population-based Study.
    Wang S; Li L; Yang J; Han N; Bao H; Wang HJ
    Cancer Prev Res (Phila); 2022 Jan; 15(1):45-54. PubMed ID: 34556493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test.
    Ronco G; Giorgi-Rossi P; Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Gillio-Tos A; Minucci D; Naldoni C; Rizzolo R; Schincaglia P; Volante R; Zappa M; Zorzi M; Cuzick J; Segnan N;
    J Natl Cancer Inst; 2008 Apr; 100(7):492-501. PubMed ID: 18364502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test.
    Kyrgiou M; Kalliala IE; Mitra A; Fotopoulou C; Ghaem-Maghami S; Martin-Hirsch PP; Cruickshank M; Arbyn M; Paraskevaidis E
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD009836. PubMed ID: 28125861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of HPV-positive women in cervical screening using results from two consecutive screening rounds.
    Polman NJ; Veldhuijzen NJ; Heideman DAM; Snijders PJF; Meijer CJLM; Berkhof J
    Int J Cancer; 2019 May; 144(9):2339-2346. PubMed ID: 30565673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world effectiveness of primary screening with high-risk human papillomavirus testing in the cervical cancer screening programme in China: a nationwide, population-based study.
    Zhao Y; Bao H; Ma L; Song B; Di J; Wang L; Gao Y; Ren W; Wang S; Wang HJ; Wu J
    BMC Med; 2021 Jul; 19(1):164. PubMed ID: 34261463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papillomavirus-based screening at extended intervals missed fewer cervical precancers than cytology in the HPV For Cervical Cancer (HPV FOCAL) trial.
    Gottschlich A; Gondara L; Smith LW; Cook D; Martin RE; Lee M; Peacock S; Proctor L; Stuart G; Krajden M; Franco EL; van Niekerk D; Ogilvie G
    Int J Cancer; 2022 Sep; 151(6):897-905. PubMed ID: 35460070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Real-world research on cervical cancer screening program and effect evaluation for Chinese population].
    Zhao YQ; Dai Y; Dang L; Kong LH; Zhang Y; Feng RM; Qiao YL; Lang JH
    Zhonghua Zhong Liu Za Zhi; 2018 Oct; 40(10):764-771. PubMed ID: 30392341
    [No Abstract]   [Full Text] [Related]  

  • 19. Switch from cytology-based to human papillomavirus test-based cervical screening: implications for colposcopy.
    Porras C; Wentzensen N; Rodríguez AC; Morales J; Burk RD; Alfaro M; Hutchinson M; Herrero R; Hildesheim A; Sherman ME; Wacholder S; Solomon D; Schiffman M
    Int J Cancer; 2012 Apr; 130(8):1879-87. PubMed ID: 21607948
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.